Evidence map›Paper›PMID 40867327›Full record

ArticleCancers2025

Intracellular Targeted Nanocapsules Containing Nanobiotherapeutic Suppress Lung, Liver, Breast and Cervix Cancer Cell Lines by Prodrug Activation or Removal of Intracellular Tyrosine.

ChenHui Zhao, Thomas Ming Swi Chang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

ChenHui ZhaoArtificial Cells and Organs Research Centre, Departments of Physiology, Medicine and Biomedical Engineering, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G1Y6, Canada.
Thomas Ming Swi ChangArtificial Cells and Organs Research Centre, Departments of Physiology, Medicine and Biomedical Engineering, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G1Y6, Canada.

Funding

Professor Chang's laboratory is supported by the Virage Centre of Excellence in High Technology award from the Quebec Ministry of Science and Education and by an unrestricted donation to McGill University from Pro-Heme Biotechnology 172810
6 · The paper itself

Abstract

backgroundMany cancer cell lines, such as Hepa 1-6 (liver), A549 (lung), Hela (cervical), and MCF7 (breast), do not overexpress tyrosinase, an enzyme needed to activate the prodrug quercetin into its active form, o-quinone. In addition, these cancers do not rely on extracellular tyrosine for growth, as they can produce small amounts intracellularly.

methodsWe investigate two therapeutic strategies using nanocapsules containing polyhemoglobin-tyrosinase (PolyHb-Tyr-nano) for action on (1) the intracellular activation of quercetin to o-quinone and (2) the depletion of intracellular tyrosine. We applied these strategies to the four cell lines listed above.

results(1) PolyHb-Tyr-nano activates quercetin intracellularly, increasing o-quinone levels and reducing cancer cell viability. (2) PolyHb-Tyr-nano alone suppresses tumor growth by lowering intracellular tyrosine. Furthermore, PolyHb-Tyr-nano shows selective cytotoxicity, with an LD

conclusionsPolyHb-Tyr-nano offers dual therapeutic functions: (1) quercetin prodrug activation and (2) intracellular tyrosine depletion.

Indexed as

artificial cellscancersmetabolic targetingnanobiotherapeuticnanocapsuleso-quinoneprodrugquercetintyrosine

Identifiers

PMID40867327
PMCPMC12384985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.